A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501

Markus, R; McBride, HJ; Ramchandani, M; Chow, V; Liu, J; Mytych, D; Fanjiang, G

Fanjiang, G (reprint author), Amgen Inc, Thousand Oaks, CA 91320 USA.

ADVANCES IN THERAPY, 2019; 36 (8): 1833

Abstract

ABP 501 [United States: AMJEVITA (TM) (adalimumab-atto); European Union: AMGEVITA((R)) (adalimumab)] is the first approved biosimilar to adalimumab [r......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索